Modalis Therapeutics Corporation
4883・Growth Market・Pharmaceuticals
Business
Modalis Therapeutics Corporation is a biotech venture engaged in the research and development of gene therapy drugs for rare genetic diseases, centered on its proprietary platform technology, the CRISPR-GNDM® Technology Platform. This technology inactivates the cleavage activity of CRISPR enzymes, functioning as a "gene switch" that turns gene expression on and off, and is characterized by a highly safe approach that does not cut DNA. Targeting the enormous unmet medical need represented by the fact that approximately 95% of the roughly 7,000 rare diseases worldwide lack treatments, the company holds a proprietary pipeline of eight programs, including for congenital muscular dystrophy type 1A (LAMA2-CMD), Duchenne muscular dystrophy (DMD), and facioscapulohumeral muscular dystrophy (FSHD). The company has established an international research organization centered on PhD researchers, with an R&D base in Waltham, Massachusetts, USA. It is listed on the Growth Market of the Tokyo Stock Exchange.
Business Model
The company adopts a hybrid model combining an "in-house model pipeline" and a "collaboration model pipeline." Under the in-house model, the company advances programs with its own funding up to a certain development stage before licensing them out to pharmaceutical companies and others, receiving upfront payments, development milestones, and royalties. Under the collaboration model, joint research is conducted using partner funding, enabling the company to secure upfront payment income at an early stage. At present, business revenue is zero, and the company is at a stage where R&D expenses are funded through capital market fundraising, such as exercise of stock acquisition rights (¥1,364 million in fiscal 2025), and external grants.
Company Strengths
CRISPR-GNDM® technology inactivates the cleavage activity of Cas9 and controls only the on/off switching of gene expression. This allows avoidance of the carcinogenesis risk and off-target cleavage risk associated with double-strand breaks in conventional genome editing, representing a key technical differentiator. Since the only variable component is the guide nucleic acid (approximately 20 bases), development efficiency for each disease is also high.
MDL-101 (for LAMA2-CMD) obtained Rare Pediatric Disease Designation (RPDD) from the US FDA in September 2024, followed by Orphan Drug Designation (ODD) in October of the same year. In IND-enabling studies, a clear survival extension effect compared to the control group was confirmed in disease model mice, consistently supporting pharmacological efficacy.
MDL-201 (for DMD) demonstrated favorable improvement effects compared to existing benchmark drugs. For MDL-103 (for FSHD), the company secured research and development support grants of ¥37,150 thousand from the XPRIZE Foundation and ¥30,116 thousand from SOLVE FSHD, and confirmed suppression of Dux4 downstream gene expression via systemic administration. The acquisition of funding and evaluation from external institutions supports the objective validity of the technology.
ENVALITH's Perspective
Performance Trend
For the first quarter of FY2026 (ending December 2026) (January to March 2026), operating loss was ¥343 million (vs. ¥633 million in the same period of the previous year), ordinary loss was ¥323 million (vs. ¥652 million in the same period of the previous year), and quarterly net loss was ¥324 million (vs. ¥652 million in the same period of the previous year). Business revenue remained at zero. The main reasons for the loss reduction were a substantial cut in research and development expenses (from ¥572 million in the same period of the previous year to ¥294 million, a decrease of approximately 49%) and a reduction in selling, general and administrative expenses (from ¥61 million in the same period of the previous year to ¥49 million). Looking at the operating loss trend over the past five fiscal years, it peaked at ¥2,063 million in FY2022, narrowed to ¥1,338 million in FY2024, but then widened again to ¥2,212 million in FY2025. At the pace of the first quarter of FY2026, the annual loss is trending toward a substantial reduction compared to the previous year. As an external environment factor, changes in U.S. healthcare and drug pricing policy and fluctuations in investment sentiment in the biotech sector continue to be conditions that could affect research and development activities.
Growth Strategy
Aiming to monetize through licensing-out of multiple pipeline programs, starting with the clinical transition of MDL-101
The lead program targeting congenital muscular dystrophy type 1A (LAMA2-CMD). Additional verification and pilot studies for the GLP toxicity study are underway. Survival extension effects have been confirmed in disease model mice. Selection and coordination of clinical trial sites is also ongoing.
Targeting myotonic dystrophy type 1, a new molecule surpassing the previous-generation molecule was successfully constructed through joint research with a US biotech company. Consistent pharmacological effects have been confirmed in animal models. Presented at ASGCT in May 2025, garnering strong interest from the expert community.
A strategic partnership with SOLVE FSHD targeting facioscapulohumeral muscular dystrophy was concluded (announced June 2025). Research and development support funds have been received, realizing a development promotion model utilizing external funding.
Through optimization of the R&D structure, research and development expenses were reduced by approximately 49% year on year. While maintaining cash and deposits of ¥2,812 million, the company continues to raise funds flexibly through the exercise of stock acquisition rights. It has been determined that funds for business continuity for the next one year have been secured.
Last updated: July 17, 2026